Reuters logo
BRIEF-Soligenix announces $1.5 mln NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942
September 20, 2017 / 10:10 AM / 3 months ago

BRIEF-Soligenix announces $1.5 mln NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942

Sept 20 (Reuters) - Soligenix Inc

* Soligenix announces $1.5 million NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below